Frontiers in immunology · 2025
Navigating disruption in the PID landscape: embracing opportunities and anticipating threats in the next ten years.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mamede Lúcia, Sabà Roser Cantenys, Van Coillie Samya, Prévot Johan, Sánchez-Ramón Silvia, Poli Cecilia, Barasa Anne, Schuller Björn W, Hendel Ayal, Garcelon Nicolas, Boersma Cornelis, Lee Pamela, Booth Claire, Notarangelo Luigi D, Drabwell Jose, Rider Nicholas L, Staal Frank J T, Burns Siobhan O, Van Hagen Martin, Pergent Martine, Rivière Jacques G, Mahlaoui Nizar
Аннотация
INTRODUCTION: The International Patient Organisation for Primary Immunodeficiencies (IPOPI) held its third edition of the Global Multi-Stakeholders' Summit, gathering key primary immunodeficiencies (PID) stakeholders and experts to discuss and foment global collaboration.
METHODS: This edition focused on the impact of genomic medicine in PID treatment, the role of digital health, including artificial intelligence, in PID care, and how to anticipate and minimise risks to ensure optimal patient access to care.
RESULTS: These discussions aimed to examine current hurdles and brainstorm feasible solutions and priorities for the PID community in these areas in the next ten years.
DISCUSSION: These discussions led to recommendations for comprehensive approaches to care and access to treatment for PID patients, suggesting actions that will bring the community closer to treatments based on real-world evidence and adjusted to patient's needs. To accomplish this, collaboration between academia, industry, regulatory authorities, and patients is crucial.
METHODS: This edition focused on the impact of genomic medicine in PID treatment, the role of digital health, including artificial intelligence, in PID care, and how to anticipate and minimise risks to ensure optimal patient access to care.
RESULTS: These discussions aimed to examine current hurdles and brainstorm feasible solutions and priorities for the PID community in these areas in the next ten years.
DISCUSSION: These discussions led to recommendations for comprehensive approaches to care and access to treatment for PID patients, suggesting actions that will bring the community closer to treatments based on real-world evidence and adjusted to patient's needs. To accomplish this, collaboration between academia, industry, regulatory authorities, and patients is crucial.